Metformin and cancer: An existing drug for cancer prevention and therapy (Review)
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Metformin is a standard clinical drug used to treat type 2 diabetes mellitus (T2DM) and polycystic ovary syndrome. Recently, epidemiological studies and meta‑analyses have revealed that patients with T2DM have a lower incidence of tumor development than healthy controls and that patients diagnosed with cancer have a lower risk of mortality when treated with metformin, demonstrating an association between metformin and tumorigenesis. In vivo and in vitro studies have revealed that metformin has a direct antitumor effect, which may depress tumor proliferation and induce the apoptosis, autophagy and cell cycle arrest of tumor cells. The mechanism underpinning the antitumor effect of metformin has not been well established. Studies have demonstrated that reducing insulin and insulin‑like growth factor levels in the peripheral blood circulation may lead to the inhibition of phosphoinositide 3‑kinase/Akt/mechanistic target of rapamycin (mTOR) signaling or activation of AMP‑activated protein kinase, which inhibits mTOR signaling, a process that may be associated with the antitumor effect of metformin. The present review primarily focuses on the recent progress in understanding the function of metformin in tumor development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726 · cited 1×
“Influence of metformin on cancer stem cells (CSCs) 8.”
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 2×
“In 2005, Evans et al (56), in a case-controlled study that included 11,876 T2DM patients, identified for the first time that metformin may reduce the risk of cancer in patients with diabetes (unadjusted odds ratio, 0.79; 95% CI, 0.67‑0.93), and that this effect was positively correlated with the dosage of metformin.”
InfluentialInsulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059 · cited 2×
“Studies in which glyconeogenesis in the liver was reduced have indicated that metformin may effectively reduce blood insulin levels by increasing the sensitivity of surrounding tissue to insulin and inhibiting the intestinal cells from absorbing glucose (76,77).”
Kern, P. A., Ranganathan, S., Li, C., Wood, L., & Ranganathan, G. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.5.e745 · Cited by 1,883 · cited 1×
“The insulin resistance that characterizes T2DM may produce large numbers of cytokines, including tumor necrosis factor α (TNF-α ), interleukin (IL)-6 and IL-1 β (49,52).”
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 2×
“However, metformin therapy did not reduce the risk of breast or prostate cancer (60).”
Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115 · cited 2×
“Additionally, metformin combined with doxorubicin may kill both CSCs and non-stem cancer cells in vitro , and the remission time was longer when compared with single-agent therapy in a xenograft mouse model (117).”
Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies
Huxley, R., Ansary-Moghaddam, A., Berrington de González, A., Barzi, F., & Woodward, M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602619 · Cited by 1,105
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Diabetes Mellitus and Risk of Colorectal Cancer: A Meta-Analysis
Larsson, S. C., Orsini, N., & Wolk, A. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji375 · Cited by 1,038 · cited 1×
“Table I summarizes the meta-analyses of the associations between diabetes and different types of cancer over a number of years (29-41).”
Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., & Vigneri, R. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0087 · Cited by 1,009
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996 · cited 1×
“The tumor incidence in 4,085 patients with diabetes treated with metformin was lower than that in the control group (7.3 vs. 11.6%), and the adjusted odds ratio was 0.63 (95% CI, 0.53‑0.75), further demonstrating that metformin may reduce the risk of tumorigenesis (58).”
InfluentialBowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner
Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.014 · Cited by 889 · cited 1×
“Kalender et al (95) demonstrated that metformin may inhibit mTORC1 in a rag GTPase-dependent manner in the absence of AMPK and TSC1/2.”
Barone, B. B. (2008) · JAMA · doi:10.1001/jama.2008.824 · Cited by 881
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880 · cited 2×
“Jiralerspong et al (65) observed that diabetic patients with breast cancer treated with metformin and neoadjuvant chemotherapy acquired a higher pathological complete response rate than those not being treated with metformin.”
Gudmundsson, J., Sulem, P., Steinthorsdottir, V., Bergthorsson, J. T., Thorleifsson, G., Manolescu, A., Rafnar, T., Gudbjartsson, D., Agnarsson, B. A., Baker, A., et al. (2007) · Nature Genetics · doi:10.1038/ng2062 · Cited by 723
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1
Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.-F., Giorgetti-Peraldi, S., & Bost, F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1769 · Cited by 616
Shackelford, D. B., Abt, E., Gerken, L., Vasquez, D. S., Seki, A., Leblanc, M., Wei, L., Fishbein, M. C., Czernin, J., Mischel, P. S., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.008 · Cited by 585 · cited 1×
“However, it is difficult to confirm whether or not metformin is more effective in the treatment of tumors without the functional LKB1-AMPK pathway (80,103).”
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033411 · Cited by 566 · cited 1×
“Furthermore, Noto et al (74) revealed that the use of metformin in patients with diabetes may reduce the risk of cancer incidence and mortality, and indicated that analysis based upon observational studies and long-term randomized controlled trials should be performed to confirm this result.”
Inoue, M. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1871 · Cited by 561
Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes
Landman, G. W. D., Kleefstra, N., van Hateren, K. J. J., Groenier, K. H., Gans, R. O. B., & Bilo, H. J. G. (2010) · Diabetes Care · doi:10.2337/dc09-1380 · Cited by 502
A meta-analysis of diabetes mellitus and the risk of prostate cancer
Kasper, J. S., & Giovannucci, E. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0410 · Cited by 491
Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer
Bodmer, M., Meier, C., Krähenbühl, S., Jick, S. S., & Meier, C. R. (2010) · Diabetes Care · doi:10.2337/dc09-1791 · Cited by 466
Shi, W.-Y., Xiao, D., Wang, L., Dong, L.-H., Yan, Z.-X., Shen, Z.-X., Chen, S.-J., Chen, Y., & Zhao, W.-L. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.13 · Cited by 308 · cited 1×
“Similarly, other studies observed that the proliferation of cells in leukemia, lymphoma, and prostate, ovarian, colon, endometrial and liver cancer was inhibited by metformin through the AMPK/mTOR pathway (88-93).”
Wright, J. L., & Stanford, J. L. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9407-y · Cited by 276
Insulin resistance and cancer: The role of insulin and IGFs
Djiogue, S., Nwabo Kamdje, A. H., Vecchio, L., Kipanyula, M. J., Farahna, M., Aldebasi, Y., & Seke Etet, P. F. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0324 · Cited by 263
Metformin and Other Biguanides in Oncology: Advancing the Research Agenda
Pollak, M. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0175 · Cited by 240 · cited 1×
“Pollak (81) demonstrated that, while metformin reduced the insulin level, no effect on the IGF-I/IGF-II level was observed (47,77,81).”
Green, A. S., Chapuis, N., Trovati Maciel, T., Willems, L., Lambert, M., Arnoult, C., Boyer, O., Bardet, V., Park, S., Foretz, M., et al. (2010) · Blood · doi:10.1182/blood-2010-02-269837 · Cited by 199
The impact of type 2 diabetes mellitus on cancer‐specific survival: A follow‐up study in sweden
Liu, X., Ji, J., Sundquist, K., Sundquist, J., & Hemminki, K. (2012) · Cancer · doi:10.1002/cncr.26420 · Cited by 97
Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma
Donadon, V. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i24.3025 · Cited by 66
Metformin and Cancer Stem Cells: Old Drug, New Targets
Bednar, F., & Simeone, D. M. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0026 · Cited by 51 · cited 10×
“Florio (124) discovered that metformin selectively inhibits the proliferation of human glioblastoma CSCs through the direct inhibition of chloride intracellular Figure 1.”
Influential
Cited by
Metformin limits osteoarthritis development and progression through activation of AMPK signalling
Li, J., Zhang, B., Liu, W.-X., Lu, K., Pan, H., Wang, T., Oh, C.-D., Yi, D., Huang, J., Zhao, L., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216713 · Cited by 300
New drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
Samuel, S., Varghese, E., Kubatka, P., Triggle, C., & Büsselberg, D. (2019) · Biomolecules · doi:10.3390/biom9120846 · Cited by 81
Metformin inhibits ROS production by human M2 macrophages via the activation of AMPK
Nassif, R. M., Chalhoub, E., Chedid, P., Hurtado-Nedelec, M., Raya, E., Dang, P. M.-C., Marie, J.-C., & El-Benna, J. (2022) · Biomedicines · doi:10.3390/biomedicines10020319 · Cited by 63
“It is the first drug of choice for the treatment of type II diabetic patients [3,4].”
BackgroundAlghandour, R., Ebrahim, M. A., Elshal, A. M., Ghobrial, F., Elzaafarany, M., & ELbaiomy, M. A. (2021) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.05.020 · Cited by 49
Metadata
- Authors
- Zi, F., Zi, H., Li, Y., He, J., Shi, Q., & Cai, Z.
- Venue
- Oncology Letters
- Publisher
- Spandidos Publications
- Published
- 2017-11-14
- Volume
- 15
- Issue
- 1
- Pages
- 683-690
- ISSN
- 1792-1074 (ISSN-L)
- 1792-1082
- OpenAlex
- W2770313364
- Cited by
- 152
- References
- 36
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.